- Entry
- $30.56
- Final
- $32.70 +7.0%
- Target
- $24.69
- Score
- -0.36
The recent rally from $19 to $30 has been fueled by a string of high-profile headlines, including the Novo Nordisk settlement, Eli Lilly product additions, and speculative excitement over peptide reclassification. However, this "growth story" carries a hidden cost: a structural compression in gross margins as HIMS pivots from high-margin compounding to lower-margin branded reselling, a trend that has already seen margins slide from 82% to 74% in the last quarter. If the upcoming May 11 earnings call reveals a …
— ORIGINAL POST ·
HIMS - Brace yourself for the next earning call
· r/stocks
· Apr 25, 2026